10-Q: Aeluma Secures $23.4M, Boosts Revenue Amidst Growth Investments
Quarterly Report
Aeluma, Inc. reported significant revenue growth and a substantial capital raise, alleviating going concern doubts, despite an increased net loss driven by operational expansion.
Summary
- Revenue for the three months ended September 30, 2025, increased by 187.9% to $1.4 million, up from $481 thousand in the prior year.
- Net loss for the quarter more than doubled to $1.5 million, compared to $730 thousand for the same period in 2024, primarily due to increased operating expenses.
- Operating expenses rose by 146.9% to $3.0 million, driven by higher material purchases, compensation, stock-based compensation, and employee benefits to support business expansion.
- The company successfully completed a public offering in September 2025, raising $23.4 million in net proceeds, and a prior offering in March 2025, raising $12.6 million net.
- Cash, cash equivalents, and certificate of deposit totaled $38.1 million as of September 30, 2025, a significant increase from $15.7 million as of June 30, 2025.
- Substantial doubt about the company's ability to continue as a going concern has been alleviated for at least the next twelve months due to the recent capital raises.
- Aeluma secured several new government contracts, including with NASA for quantum computing/sensing and the U.S. Navy for imaging sensors and high-speed photodetectors.
- Total remaining performance obligations under government contracts amounted to $9.0 million as of September 30, 2025.
- The company's disclosure controls and procedures were deemed not effective as of September 30, 2025, due to insufficient finance department staffing, with remediation efforts underway including the hiring of a new CFO.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive. While the net loss increased significantly, this is largely attributable to substantial investments in scaling operations and R&D, which are typical for an early-stage growth company. The successful capital raises have dramatically improved liquidity and alleviated going concern doubts, providing a strong foundation for future growth. New government contracts validate the technology and market potential. The internal control issue is a concern but is being actively addressed by management.
Positives
- Revenue increased by 187.9% to $1.4 million for the three months ended September 30, 2025, demonstrating strong top-line growth.
- Successfully raised $23.4 million in net proceeds from a public offering in September 2025, significantly bolstering the company's cash position.
- The successful capital raises have alleviated substantial doubt about the company's ability to continue as a going concern for at least the next twelve months.
- Secured multiple new government contracts with agencies like NASA and the U.S. Navy, indicating strong demand and validation for Aeluma's advanced technology.
- Cash, cash equivalents, and certificate of deposit increased to $38.1 million, providing ample liquidity for operational growth and strategic initiatives.
- Net cash used in operating activities improved to $815 thousand for the three months ended September 30, 2025, from $931 thousand in the prior year, despite increased operational scale.
- Expanded physical footprint by commencing a new 2,400 sq. ft. office lease to accommodate anticipated headcount growth and future expansion.
Negatives
- Net loss increased by 104.3% to $1.5 million for the three months ended September 30, 2025, compared to $730 thousand in the prior year.
- Operating expenses surged by 146.9% to $3.0 million, outpacing revenue growth and contributing to the increased net loss.
- Disclosure controls and procedures were assessed as not effective as of September 30, 2025, due to insufficient finance department staffing, posing a risk to financial reporting integrity.
- The company continues to operate at a net loss, indicating it is not yet profitable.
Risks
- A prolonged U.S. federal government shutdown could materially and adversely affect business, operations, and legal proceedings, including delays in regulatory approvals and access to government data.
- Federal budget and debt-ceiling disputes may adversely affect capital markets, investor confidence, and the company's ability to execute financing transactions, particularly as a small-cap/microcap issuer.
- The company has a limited operating history, and its future success is subject to numerous uncertainties and risks inherent in developing a new business.
- Despite recent capital raises, there is no assurance that funds will be sufficient to carry out all aspects of the business plan, and the company continues to face risks typical of early-stage companies, including limited capital resources and operational challenges.
- The ineffectiveness of disclosure controls and procedures due to insufficient finance staffing could lead to errors or delays in financial reporting.
Future Outlook
Aeluma plans to continue developing its core technology, focusing on manufacturing high-performance semiconductor technologies that scale for mass markets. The company intends to mature its manufacturing processes, expand business development and marketing efforts, further engage with manufacturing partners, and pursue volume production and commercialization. Proceeds from recent offerings will be used for business development, scaling manufacturing operations, hiring new employees, and general corporate purposes. Management believes existing cash and projected revenues will be sufficient to meet working capital and capital expenditure requirements for at least the next twelve months.
Management Comments
- Management has assessed our financial position and operating plan and determined that the previously reported substantial doubt about our ability to continue as a going concern has been alleviated.
- Our management team is in the process of implementing remediation measures for disclosure controls, including hiring a chief financial officer with public company financial reporting experience, and planning to add qualified accounting personnel and enhance internal control processes and documentation.
Industry Context
Aeluma operates in the high-growth semiconductor industry, specializing in optoelectronic and electronic devices for diverse applications including mobile, automotive, AI, defense & aerospace, communication, AR/VR, high-performance computing, and quantum computing. Its pioneering technique of using high-performance compound semiconductors on large-diameter substrates positions it to address the increasing demand for scalable, cost-effective, high-performance semiconductors in mass markets. The new government contracts align with broader industry trends towards advanced sensing, quantum computing, and next-generation communication technologies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Financial Officer | NA | Christopher Stewart | 2025-08-04 | Appointment to support business expansion and address financial reporting requirements. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure Controls and Procedures | Management concluded that disclosure controls and procedures were not effective as of September 30, 2025, due to insufficient staffing resources in the finance department leading to inadequate precision, evidence, or timeliness in review controls. | 2025-09-30 | Potential for errors or delays in financial reporting. Remediation efforts are underway, including hiring a new CFO and planning to add qualified accounting personnel and enhance internal control processes. |
Legal Proceedings
- Not currently involved in any material legal proceedings.
- Anticipates involvement in legal proceedings, claims, and litigation arising in the ordinary course of business, which could incur material expenses or have an adverse effect on financial statements if outcomes are unfavorable.
Related Party Transactions
- Director Steven DenBaars adopted a Rule 10b5-1 trading arrangement on June 23, 2025, for the sale of up to 130,000 shares between October 6, 2025, and May 6, 2026.
- Mr. DenBaars terminated the 10b5-1 Plan on September 16, 2025, and no sales were made pursuant to the plan.
Stakeholder Impact
- **Shareholders**: Significant dilution from recent public offerings (increased shares outstanding), but also improved liquidity and alleviated going concern risk, potentially increasing investor confidence. Termination of director's 10b5-1 plan removes potential selling pressure.
- **Employees**: Plans for hiring new employees and expansion of facilities indicate growth opportunities. Stock-based compensation is a significant component of overall compensation.
- **Customers**: New government contracts and ongoing R&D services demonstrate continued engagement and value proposition.
- **Creditors**: Improved financial health and liquidity from capital raises reduce credit risk.
- **Suppliers**: Increased material purchases to support product and service delivery suggest higher demand for supplier inputs.
Next Steps
- Continue to develop technology, including novel materials and devices based on core intellectual property.
- Mature manufacturing processes to further commercialization traction.
- Expand business development and marketing efforts.
- Further engage with manufacturing partners and continue efforts toward volume production and commercialization.
- Use net proceeds from offerings for business development, scaling manufacturing operations, hiring new employees, and general corporate purposes.
- Implement remediation measures for disclosure controls, including adding qualified accounting personnel and enhancing internal control processes and documentation.
Key Dates
| Date | Description |
|---|---|
| 2021-04-01 | Company commenced a 5-year operating lease for its primary facility in Goleta, California. |
| 2023-07-01 | Company determined one of two lease extension options for its primary facility was reasonably certain of exercise, leading to remeasurement of ROU asset and lease liability. |
| 2024-08-05 | Beginning of period for issuance of convertible promissory notes in a private note financing. |
| 2024-08-27 | End of period for issuance of convertible promissory notes in a private note financing, totaling $3.1 million. |
| 2024-08 | Received a contract by NASA to develop quantum dot photonic integrated circuits (PICs) on silicon. |
| 2024-09 | Received an $11.7 million contract with U.S. Defense Advanced Research Projects Agency (DARPA) for heterogeneous integration technology. |
| 2025-03-25 | Company determined a Conversion Event had occurred for convertible notes, leading to conversion of $3.1 million in principal into 898,573 shares of common stock. |
| 2025-03-26 | Company entered into an Underwriting Agreement for a public offering of 2,285,714 shares at $5.25 per share (March Offering). |
| 2025-03-27 | Underwriter exercised its over-allotment option in full for the March Offering. |
| 2025-03-28 | March Offering closed, generating $12.6 million in net proceeds. |
| 2025-04 | Received a contract with the U.S. Department of Energy to develop commercially viable, low-cost shortwave infrared (SWIR) photodetectors. |
| 2025-06 | Received a contract with the U.S. Navy for low size, weight, and power imaging sensors for next-generation submarine systems. |
| 2025-06 | Received a contract with the U.S. Navy for up to $1.3 million in funding to accelerate development of high-speed photodetectors. |
| 2025-06-23 | Director Steven DenBaars adopted a Rule 10b5-1 trading arrangement for the sale of up to 130,000 shares. |
| 2025-08-04 | Christopher Stewart appointed as Chief Financial Officer. |
| 2025-09-05 | Company commenced a new five-year operating lease for an office adjacent to its existing facility in Goleta, California. |
| 2025-09-16 | Director Steven DenBaars terminated his Rule 10b5-1 trading arrangement. |
| 2025-09-17 | Company entered into an Underwriting Agreement for the issuance and sale of 1,700,000 shares of common stock at $13.00 per share (September Offering). |
| 2025-09-18 | Underwriters exercised their option to purchase an additional 255,000 shares of common stock in connection with the September Offering. |
| 2025-09-19 | September Offering closed, generating $23.4 million in net proceeds. |
| 2025-09-21 | Company commenced a 5-year operating lease for an office in Goleta, California. |
| 2025-09-30 | End of the quarterly reporting period. |
| 2025-11-10 | Date as of which 17,857,863 shares of common stock were outstanding. |
| 2025-11-12 | Filing date of the Quarterly Report on Form 10-Q. |
Recommendation
buyAeluma, Inc. presents a compelling 'buy' opportunity for investors with a higher risk tolerance and long-term horizon. The company has successfully executed two significant capital raises, injecting over $36 million in net proceeds, which has fundamentally transformed its liquidity position and, crucially, alleviated prior going concern doubts. This financial stability provides the necessary runway for an early-stage technology company to scale. While the net loss increased, it is a direct consequence of aggressive investment in R&D, manufacturing expansion, and talent acquisition, all vital for commercializing its disruptive semiconductor technology. The substantial growth in revenue (187.9%) and the securing of multiple high-profile government contracts (NASA, U.S. Navy, DARPA, DOE) validate the market demand and technological prowess. The identified weakness in disclosure controls is a concern, but management has promptly addressed it by hiring a new CFO and outlining clear remediation steps. The long-term potential across diverse, high-growth sectors like AI, quantum computing, and defense, combined with a strengthened balance sheet, outweighs the short-term operational losses and control issues.
Keywords
Semiconductor, Optoelectronics, Quantum Computing, AI, Defense & Aerospace, Communication, AR/VR, High-Performance Computing, Sensing, Capital Raise, Government Contracts, SEC Filing, 10-Q
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.